A Phase 1, Dose-Escalation Study in Healthy Volunteers to Evaluate the Pharmacokinetics, Safety, and Tolerability of GS-1427 Following Single and Multiple Dosing
Latest Information Update: 20 Jan 2025
At a glance
- Drugs GS-1427 (Primary)
- Indications Inflammatory bowel diseases
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
Most Recent Events
- 04 Feb 2022 Planned End Date changed from 20 Apr 2022 to 15 Nov 2022.
- 04 Feb 2022 Status changed from not yet recruiting to recruiting.
- 26 May 2021 New trial record